ICN GALENIKA FIRST QTR RESULTS
ICN Galenika, based in the former Yugoslav capital Belgrade, recorded a turnover of $120 million for the first quarter of 1992, according to the Tanjug news agency, quoting company sources.
As a result, each share in the company will earn a profit of approximately 40 cents for shareholders. ICN Galenika will this year produce about 600 pharmaceutical products for sale in 60 countries, the news report added. The company, which is an affiliate of ICN Pharmaceuticals, had full-year 1991 sales of around $380 million, which means that on a pro rata basis, the first quarter's performance indicates a 26% improvement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze